Cladribine

The benefits of immune reconstitution therapy in MS 1:28
The benefits of immune reconstitution therapy in MS
Celia Oreja-Guevara • 28 Oct 2022
Precision medicine in MS and factors to consider when making treatment decisions 2:18
Precision medicine in MS and factors to consider when making treatment decisions
Augusto Miravalle • 8 Apr 2022
ChariotMS: the first DMT trial in advanced multiple sclerosis 3:19
ChariotMS: the first DMT trial in advanced multiple sclerosis
Klaus Schmierer • 1 Jul 2022
Changes in the MS treatment landscape over the last 2 years 6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri • 22 Mar 2022
Study of patients with RRMS treated with cladribine 4:17
Study of patients with RRMS treated with cladribine
Virginia Meca-Lallana • 28 Feb 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS 3:57
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS
Gavin Giovannoni • 1 Mar 2022
COVID-19 outcomes in patients with relapsing MS receiving cladribine 2:22
COVID-19 outcomes in patients with relapsing MS receiving cladribine
Gavin Giovannoni • 1 Mar 2022
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS 1:11
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS
Namita Tundia • 25 Feb 2022
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs 1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
Current treatments for primary and secondary progressive multiple sclerosis 4:46
Current treatments for primary and secondary progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Determining the optimal treatment strategy in MS 4:18
Determining the optimal treatment strategy in MS
Tanuja Chitnis • 23 Feb 2021
Treating MS: new therapies and COVID-19 3:23
Treating MS: new therapies and COVID-19
Abhijit Chaudhuri • 21 Oct 2020
The content of VJNeurology is intended for healthcare professionals